|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Short-term investments | ||||||||||||||||||||
| Prepaid expenses | ||||||||||||||||||||
| Short-term investments, restricted | ||||||||||||||||||||
| Restricted short term investments | ||||||||||||||||||||
| Prepaid insurance | ||||||||||||||||||||
| Other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Loans receivable | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued salaries, wages and benefits | ||||||||||||||||||||
| Accrued legal and professional | ||||||||||||||||||||
| Accrued legal and professional fees | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Liabilities subject to compromise | ||||||||||||||||||||
| Warrant and other non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Mezzanine equity | ||||||||||||||||||||
| Series A Convertible Preferred stock, $0.0001 par value, 12,000,000 shares authorized; 300,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Series A Convertible Preferred Stock | ||||||||||||||||||||
| Total series A Convertible Preferred stock, $0.0001 par value, 12,000,000 shares authorized; 300,000 shares issued and outstanding as of June 30, 2026 and December 31, 2025 | ||||||||||||||||||||
| Stockholders’ equity | ||||||||||||||||||||
| Class A common stock, $0.0001 par value, 450,000,000 shares authorized; 16,211,365 and 16,211,365 shares issued as of June 30, 2026 and December 31, 2025, respectively, 16,096,296 and 16,096,296 shares outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Common Class A | ||||||||||||||||||||
| Total class A common stock, $0.0001 par value, 450,000,000 shares authorized; 16,211,365 and 16,211,365 shares issued as of June 30, 2026 and December 31, 2025, respectively, 16,096,296 and 16,096,296 shares outstanding as of June 30, 2026 and December 31, 2025, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ equity | ||||||||||||||||||||
| Total liabilities, mezzanine equity and stockholders’ equity | ||||||||||||||||||||
Loading...
